pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

pharmazz PRESS RELEASE ARCHIVE

May 31, 2023

Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients

Mar 20, 2023

Pharmazz Inc. Announces Key Publications Regarding the Role of Adrenergic Receptors in Venous Blood Return to Treat Shock

Oct 31, 2022

Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke

Oct 31, 2022

Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke

Oct 26, 2022

Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress

Sep 13, 2022

Pharmazz Inc. Presents Data From its Positive Phase III Study of Centhaquine (PMZ-2010) as a Resuscitative Agent in Hypovolemic Shock Patients at Upcoming Military Health System Research Symposium

Aug 29, 2022

Pharmazz Inc. announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates

May 25, 2022

Pharmazz Inc. Announces Positive Results of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke

Mar 10, 2022

Pharmazz Inc. announces FDA clearance of an IND application for a Phase II clinical trial of centhaquine (PMZ-2010) in COVID-19 patients with ARDS

Feb 17, 2022

Pharmazz Inc. Announces Completion of Enrollment of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke

Feb 3, 2022

Pharmazz Inc. submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates

Sep 29, 2021

US FDA approved IND submitted by Pharmazz, Inc. to initiate a phase III clinical trial of centhaquine in patients with hypovolemic shock

Oct 28, 2019

Pharmazz submits application for marketing authorization of centhaquine (PMZ-2010), a first-in-class investigational product, for patients with hypovolemic shock

Oct 18, 2017

Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management

Feb 3, 2017

Pharmazz, Inc. initiates human phase II studies of PMZ-2010 for the treatment of hemorrhagic shock and presents data at the Society of Critical Care Medicine Annual Meeting

Dec 9, 2016

Global Brain Edema Pipeline Review, H2 2016 Featuring FibroGen, Pharmazz and Remedy Pharmaceuticals - Research and Markets

Nov 30, 2016

Pharmazz, Inc. advances its product pipeline for the treatment of stroke, strengthens patent portfolio and presents hemorrhagic shock data at the American Heart Association

Apr 22, 2016

Pharmazz, Inc. strengthens its patent portfolio with Notice of Issuance for PMZ-2123 (BQ123) in the treatment of diabetic ketoacidosis

Google Analytics Alternative